GAMMA Investing LLC Has $194,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

GAMMA Investing LLC grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 19.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,493 shares of the medical equipment provider’s stock after purchasing an additional 408 shares during the period. GAMMA Investing LLC’s holdings in Hologic were worth $194,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Arizona State Retirement System increased its stake in Hologic by 0.3% during the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock worth $4,810,000 after acquiring an additional 172 shares during the period. Lincoln National Corp raised its stake in Hologic by 4.0% in the fourth quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock valued at $334,000 after purchasing an additional 178 shares in the last quarter. Allworth Financial LP lifted its position in Hologic by 39.3% during the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 179 shares during the period. Great Lakes Retirement Inc. grew its stake in Hologic by 1.6% during the fourth quarter. Great Lakes Retirement Inc. now owns 11,859 shares of the medical equipment provider’s stock worth $847,000 after buying an additional 186 shares in the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Hologic by 11.5% in the 4th quarter. Parallel Advisors LLC now owns 1,828 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 189 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

NASDAQ HOLX opened at $72.21 on Friday. The company has a market capitalization of $16.85 billion, a price-to-earnings ratio of 36.84, a PEG ratio of 2.38 and a beta of 1.00. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $82.45. The stock has a fifty day simple moving average of $74.67 and a 200 day simple moving average of $74.11. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the company earned $1.06 earnings per share. The firm’s revenue was down .8% compared to the same quarter last year. Sell-side analysts expect that Hologic, Inc. will post 4.08 EPS for the current year.

Analyst Ratings Changes

HOLX has been the topic of several analyst reports. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. JPMorgan Chase & Co. raised their price objective on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Evercore ISI boosted their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Finally, Argus raised their price target on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Five analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $85.60.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.